Autoimmune B-cell lymphopenia after successful adoptive therapy with telomerase-specific T lymphocytes

Stefano Ugel, Elisa Scarselli, Manuela Iezzi, Carmela Mennuni, Tania Pannellini, Francesco Calvaruso, Barbara Cipriani, Raffaele De Palma, Lucia Ricci-Vitiani, Elisa Peranzoni, Piero Musiani, Paola Zanovello, Vincenzo Bronte

Research output: Contribution to journalArticle

Abstract

Telomerase reverse transcriptase (TERT) is a good candidate for cancer immunotherapy because it is overexpressed in 85% of all human tumors and implicated in maintenance of the transformed phenotype. TERT-based cancer vaccines have been shown to be safe, not inducing any immune-related pathology, but their impact on tumor progression is modest. Here we show that adoptive cell therapy with the use of high-avidity T lymphocytes reactive against telomerase can control the growth of different established tumors. Moreover, in transgenic adenocarcinoma mouse prostate mice, which develop prostate cancer, TERT-based adoptive cell therapy halted the progression to more aggressive and poorly differentiated tumors, significantly prolonging mouse survival.We also demonstrated that human tumors, including Burkitt lymphoma, and human cancer stem cells, are targeted in vivo by TERT-specific cytotoxic T lymphocytes. Effective therapy with T cells against telomerase, different from active vaccination, however, led to autoimmunity marked by a consistent, although transient, B-cell depletion in primary and secondary lymphoid organs, associated with alteration of the spleen cytoarchitecture. These results indicate B cells as an in vivo target of TERT-specific cytotoxic T lymphocytes during successful immunotherapy.

Original languageEnglish
Pages (from-to)1374-1384
Number of pages11
JournalBlood
Volume115
Issue number7
DOIs
Publication statusPublished - Feb 18 2010

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Fingerprint Dive into the research topics of 'Autoimmune B-cell lymphopenia after successful adoptive therapy with telomerase-specific T lymphocytes'. Together they form a unique fingerprint.

Cite this